Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies

Author： Nedergaard Mette K.   Hedegaard Chris J.   Poulsen Hans S.  

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.26, Iss.2, 2012-04, pp. : 83-99

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cetuximab-Associated Elongation of the Eyelashes: Case Report and Review of Eyelash Trichomegaly Secondary to Epidermal Growth Factor Receptor Inhibitors

By Cohen Philip R.   Escudier Susan M.  

American Journal of Clinical Dermatology, Vol. 12, Iss. 1, 2011-02 ,pp. : 63-67

Adis International

Access to resources Recommend Favorite

Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer†

By Garnock-Jones Karly P.   Keating Gillian M.   Scott Lesley J.  

BioDrugs, Vol. 24, Iss. 3, 2010-06 ,pp. : 207-209

Adis International

Access to resources Recommend Favorite

Targeting Nerve Growth Factor in Pain: What is the Therapeutic Potential?

By Watson Judy J.   Allen Shelley J.   Dawbarn David  

BioDrugs, Vol. 22, Iss. 6, 2008-01 ,pp. : 349-359

Adis International

Access to resources Recommend Favorite

Tumor Necrosis Factor Receptor Pre-Ligand Assembly Domain is an Important Therapeutic Target in Inflammatory Arthritis

By Deng Guo-Min  

BioDrugs, Vol. 21, Iss. 1, 2007-01 ,pp. : 23-29

Adis International

Access to resources Recommend Favorite

Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor: Current Status and Future Challenges in Cancer Therapy

By Hsu Jerry Y.   Wakelee Heather A.  

BioDrugs, Vol. 23, Iss. 5, 2009-10 ,pp. : 289-304

Adis International

Access to resources Recommend Favorite